论文部分内容阅读
资料来源:FDA Patient Safety News 发布日期:2010.3.5为帮助临床医师评估治疗糖尿病的药品Byetta(艾塞那肽)的获益与风险,FDA要求在药品标签上加上有致肾损伤风险的信息。自从2005年4月至2008年10月,FDA收到了78份服用Byetta患者肾功能改变的报告。一些患者在服药前就已经有肾脏疾病和其他引起肾脏问题的风险因素。62例患者出现急性肾衰竭,16例患者出现肾功能不全。在此期间总计有超过660万份Byetta处方开给患者,所以这些报道的病例只占使用该药治疗患者
Source: FDA Patient Safety News Date: March 31, 2010 To help clinicians evaluate the benefits and risks of Byetta, a drug used to treat diabetes, FDA requires labeling of drug products with information on the risk of developing kidney damage. Since April 2005 to October 2008, the FDA received 78 reports of changes in renal function in patients taking Byetta. Some patients already have kidney disease and other risk factors that cause kidney problems before taking medications. 62 cases of acute renal failure, 16 patients with renal insufficiency. During this period a total of more than 6.6 million Byetta prescriptions were opened to patients, so these reported cases accounted for only the use of the drug treatment of patients